The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

As the World Health Organization initiates a new agreement for coordinating global responses to future pandemics, the future ...

Novavax, Inc. (“Novavax”) announced that FDA approved its Biologics License Application (“BLA”) for Nuvaxovid™ for active ...

On May 20, BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The approval of Nuvaxovid for use in older and high-risk adults ...

In a video posted to social media on Tuesday, HHS Secretary Robert F. Kennedy, Jr. claimed that there is a lack of clinical ...

An FDA advisory committee unanimously recommended Thursday that the next COVID vaccine should be a monovalent one in the JN.1 ...

Moderna MRNA announced that it has submitted a regulatory filing with the FDA seeking approval for an updated version of its ...

Last week saw Novavax receive full approval from the US Food and Drug Administration (FDA) for its COVID-19 vaccine, but with ...

HHS Secretary Robert F. Kennedy Jr. says the CDC no longer recommends COVID-19 vaccines for healthy pregnant women & children ...

A panel of advisers to the U.S. Food and Drug Administration (FDA) has recommended that for the upcoming fall and winter immunization campaigns, COVID-19 vaccine makers should formulate their shots to ...